Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Death unexplained; This is a spontaneous report from a contactable physician downloaded from the Regulatory Authority-WEB (Regulatory Authority number: FR-AFSSAPS-CF20210115). An 81-year-old male patient received the first single dose of BNT162B2 (COMIRNATY; lot EJ6788) intramuscular, on 25Jan2021, in early afternoon, for COVID-19 immunisation. The patient was residing in long-term care unit. Medical history included supplemented hypothyroidism, peripheral arterial occlusive disease, kidney failure chronic (chronic renal failure with episode of hyperuricaemia), peptic ulcer haemorrhage (hemorrhagic peptic ulcers repetitive since 1980), atrial fibrillation, type 2 diabetes mellitus, dyslipidaemia, mixed dementia, ischaemic heart disease, arterial hypertension, livedo reticularis, infra-renal abdominal aortic aneurysm in 2007, loose calcified aortic stenosis, notion of transient ischemic attack before 2010, partial gastrectomy with gastro-jejunal anastomosis in 1995, moderate intestinal gastritis / duodenal stump ulcer treated with proton-pump inhibitors. Concomitant medications were not reported. Without any clinical warning sign (absence of oedema, urticaria, respiratory and cardiocirculatory failure), the patient''s death was observed on 27Jan2021 at 17:30 (death unexplained). It was unknown if an autopsy was performed. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: Death unexplained
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166